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Aims Several large studies have documented the outcome of transvenous lead extraction (TLE), focusing on laser and
mechanical methods. To date there has been no large series addressing the results obtained with rotational lead
extraction tools. This retrospective multicentre study was designed to investigate the outcomes of mechanical and
rotational techniques.
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Methods
and results
Data were collected on a total of 2205 patients (age 66.0 ± 15.7 years) with 3849 leads targeted for extraction in
six European lead extraction centres. The commonest indication was infection (46%). The targeted leads included
2879 pacemaker leads (74.8%), 949 implantable cardioverter-defibrillator leads (24.6%), and 21 leads for which
details were unknown; 46.6% of leads were passive fixation leads. The median lead dwell time was 74 months
[interquartile range (IQR) 41–112]. Clinical success was obtained in 97.0% of procedures, and complete extraction
was achieved for 96.5% of leads. Major complications occurred in 22/2205 procedures (1%), with a peri-operative
or procedure-related mortality rate of 4/2205 (0.18%). Minor complications occurred in 3.1% of procedures. A to-
tal of 1552 leads (in 992 patients) with a median dwell time of 106 months (IQR 66–145) were extracted using the
Evolution rotational TLE tool. In this subgroup, complete success was obtained for 95.2% of leads with a proce-
dural mortality rate of 0.4%.
...................................................................................................................................................................................................
Conclusion Patient outcomes in the PROMET study compare favourably with other large TLE trials, underlining the capability
of rotational TLE tools and techniques to match laser methods in efficacy and surpass them in safety.
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Introduction
Transvenous lead extraction (TLE) plays an essential role in the
long-term management of patients with cardiac implanted electronic
devices. Fibrosis and calcification along implanted leads becomes
increasingly likely with longer dwell times and simple traction is often
not enough to achieve complete removal. Mechanical sheaths were
the first widely used tool but were only moderately effective.1
Powered sheaths, utilizing either laser or radiofrequency energy to
break down areas of fibrosis, were the next development. Of the
two, laser powered sheaths gained the most traction and several
large studies have shown them to achieve very high clinical success
rates.2,3 Concerns have been raised about the risk of major complica-
tions when using laser sheaths.1,2,4
Rotational dissecting sheaths, characterized by a handle trigger-
driven rotational dissecting tip at the end of a flexible sheath, have
been available for this application for just over a decade.5 Rotational
tools have been associated with greater efficacy than other non-laser
methods in extracting all components of the targeted leads.6 Safety
data from small case series have been promising,6 but data from
larger series, such as that available for laser methods,3,7 have been
lacking. The range of rotational tools has continued to expand, as has
the range of accessories for use in association with them to enhance
safety and efficacy.6,8–11
To date, there is a lack of large volume data on advanced mechani-
cal lead extraction techniques and tools. The PROMET (Patient-
Related Outcomes of Mechanical lead Extraction Techniques) study
was designed to address this by collecting data from consecutive
patients treated in high-volume extraction centres in which rotational
tools were the preferred method for TLE in cases not amenable to
simple traction.
Methods
Patient population
Patient data were collected from six European lead extraction centres
that had maintained a comprehensive record of lead extraction proce-
dures. Five of the six centres fulfilled the criteria of a high-volume extrac-
tion centre (>30 procedures/year). Depending on the availability of
sufficient data sets in different study centres and based on the retrospec-
tive design of this study, the starting point of data collection differed be-
tween the centres from as early as January 2005. The local review board
at all investigational sites approved the research protocol. The results
obtained were analysed retrospectively with regard to efficacy and safety.
Definitions
Success and failure were defined according to the definitions of the 2017
Heart Rhythm Society and the 2018 European Heart Rhythm Association
expert consensus.12 In brief, complete success for the extraction of an in-
dividual lead was defined as the removal of all components of that lead
from the vascular space without the occurrence of a fatal or permanently
disabling complication. A procedure was considered a clinical success if it
attained the intended clinical outcome and did not involve the retention
of any lead portion >4 cm in length.
Complications were adjudicated by a committee including representa-
tives from each contributing centre. A complication was considered to
have occurred if an undesired consequence of the extraction procedure
suffering or disability, prolongation of the hospital admission, or a need
for additional intervention or pharmacological therapy. Based on defini-
tions in prior expert consensus papers,12–14 a complication was classed as
serious if it led to the death of the patient or to persistent disability or if it
required a substantial intervention such as cardiac surgery, pericardio-
centesis, or vascular surgery. Fatalities were judged to be related to the
extraction procedure if they occurred on the day of the procedure or as
a consequence of a complication of the procedure.
Statistics
Categorical variables are presented as numbers and percentages.
Continuous variables are presented as mean ± standard deviation or as
median and interquartile range (IQR), as appropriate. Differences be-
tween groups were analysed by two-sample t-test. A P-value of <0.05
was considered significant.
Results
Patient and lead characteristics
Data were obtained for 2205 patients (69% male, age 66.0 ±
15.7 years; Table 1) with 3849 targeted leads for TLE. The mean dwell
time of the targeted leads averaged 84.8 ± 61.9 months, with a me-
dian of 74 months (IQR 41–112). Seventy-five percent of the targeted
leads were pacemaker leads, 25% implantable cardioverter-
defibrillator leads.
The most common indication for TLE was infection, present in
46%, but declined non-significantly over the course of the study, rep-
resenting the primary indication in 47.0% in the first half of each
centre’s experience compared to 44.0% in the second half.
Techniques and equipment
In all study centres a superior, subclavian approach was chosen as the
primary option for lead extraction procedures. Most procedures
(68.4%) were performed by cardiac surgeons, working in all cases in
either a hybrid theatre (95.6%) or a standard operating theatre
(4.4%). The remainder were performed by cardiologists/electro-
physiologists, generally working in an electrophysiology laboratory
(99.2%). All procedures not performed by a cardiac surgeon were
performed with cardiac surgical stand-by including the availability of
extracorporeal circulation and a perfusionist.
For leads that could not be extracted by simple traction, a multi-
step lead extraction approach (individual to each study centre) was
performed. A locking stylet (Liberator, Cook Medical, USA) was gen-
erally used as the first of these additional steps, making it the most
commonly used item of specialized extraction equipment (Figure 1).
What’s new?
• Largest series of data published on clinical outcomes of a rota-
tional lead extraction tool.
• The Evolution rotational extraction sheath shows a good
safety and efficacy performance, especially in long implanted
leads.
• The risk for superior vena cava injury when using the
Evolution rotational extraction tool is very low.
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For 940 leads with a median dwell time of 71 months (IQR 48–93),
the locking stylet alone allowed enough additional traction to remove
the lead. In other cases, this traction permitted the use of the lead as
a rail to guide an extraction sheath.
Dissection sheaths included simple polypropylene models (Byrd
Dilator Sheath, Cook Medical, USA), PTFE sheaths (Cook Medical,
USA), laser sheaths (SLS II, Philips, USA), and rotational tools
(Evolution and Evolution RL, Cook Medical, USA; Tightrail, Philips,
USA). Laser sheaths were used for 139 leads (3.6%) with a median
dwell time of 57 months (IQR 38–81). Their use was confined to the
first half of the case series and they were used in only three centres,
accounting for 21% of leads extracted in one centre, fewer than 1%
in the other two.
Where a subclavian approach failed or was expected to be impos-
sible, a femoral or an internal jugular approach was performed. In
these cases, a variety of snares were used, predominantly the
Needle’s Eye (Cook Medical, USA) which accounted for 70% of all
snare usage.
.................................................................................................
Table 1 Patient and lead characteristics
Patient characteristics
Patient number 2205
Age 66.0 ± 15.7 years
Gender
Male 69%
Female 30%
Unknown 1%
Left ventricular ejection fraction 38.3 ± 16.1%
NYHA class (n = 187)
Class 1 18.7%
Class 2 25.1%
Class 3 40.6%
Class 4 15.5%
Diabetes mellitus (n = 419) 22.7%
Chronic renal disease (n = 393) 57.3%
Cardiomyopathy (n = 542)
DCM 40.8%
ICM 59.2%
Previous cardiac surgery (n = 601) 27.8%
Number of targeted leads 3849
74.8% pacemaker leads
24.6% ICD leads
0.6% information not available
Implant duration
Mean implant duration 84.7 ± 61.8 months
Median implant duration 74 months (IQR 41–112)
Localisation of leads
Right atrium 1167 (30.3%)
Right ventricle 2238 (58.1%)
Coronary sinus tributary 395 (10.3%)
SVC 8 (0.2%)
Fragment or unknown 41 (1.1%)
Fixation mechanism
Active fixation 1560 (40.6%)
Passive fixation 1795 (46.6%)
Information not available 494 (12.8%)
DCM, dilated cardiomyopathy; ICD, implantable cardioverter-defibrillator; ICM,
ischaemic cardiomyopathy; IQR, interquartile range; NYHA, New York Heart
Association; SVC, superior vena cava.
Figure 1 Temporal trends in the equipment used in the
PROMET cohort. Laser equipment was almost abandoned by all
centres within the first half of the experience. There was increasing
uptake of rotational dissection sheaths instead of traction-only or la-
ser methods, with a high and constant background usage of locking
stylets.
Figure 2 Safety endpoints of the PROMET study in the overall
cohort and in the subset in whom rotational dissection sheaths
were used.
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Safety
Major complications occurred in 22 cases (1.0%; Table 3, Figure 2),
and minor complications in 3.1%. Procedure-related mortality oc-
curred in four patients (0.18%), three of whom had systemic infection
as the indication for extraction.
Efficacy and efficiency
Among the entire study group (2205 patients/3849 leads), complete
technical success was obtained in the extraction of 96.5% of leads,
with a clinical success rate of 97.0% of procedures.
Rotational dissection tools
Subgroup analysis was performed for the use of the Evolution or the
Evolution RL rotational TLE devices, which were used for 1552 leads
in 992 patients. Other devices of the Evolution group including the
Evolution Shortie, the Evolution Shortie RL, and the Evolution outer
sheath were not included unless used in association with the full-
length Evolution or Evolution RL. The Tightrail rotational extraction
sheath was not included as the design of this tool is substantially dif-
ferent, and the device was used for only 12 leads.
Leads removed using the Evolution rotational tools had a longer
dwell time than others (Table 2, Figure 3). Despite the implant dura-
tion of the leads extracted in the Evolution group, complete proce-
dural success was only 2.1% lower than in the non-Evolution group
(95.2% vs. 97.3%).
The major complications encountered in the Evolution group pre-
dominantly consisted of right ventricular injuries (Table 3). One case
of injury to the right atrium and adjacent intrapericardial superior
vena cava (SVC) occurred, and one late haemothorax requiring per-
cutaneous drainage (Table 3) but no acute injuries to the extraperi-
cardial part of the SVC were encountered.
Discussion
The PROMET study is the largest study to report on efficacy and
safety outcomes in patients undergoing mechanical TLE and is com-
parable in size to the largest series of laser extraction (Table 4). The
key findings are:
(1) Mechanical tools can deliver a level of efficacy that is equivalent to
that of laser powered sheaths.
(2) The use of mechanical tools is associated with a low procedural risk
for major and minor complications. The nature of major complica-
tions differs from that reported in any of the large series describing
laser-based TLE methods, particularly the lower incidence of proce-
dural injuries to the SVC.
Safety
The list of adverse events encountered in the PROMET cohort is re-
markable for the low incidence of acute injuries to the SVC, which, in
contrast, account for most of the fatal complications of laser TLE.
The low incidence of injury to the SVC demonstrated in the
PROMET study constitutes a major advance in TLE. Even in the ex-
pert hands represented by the LEXICON and ELECTRa investiga-
tors, vascular tears/avulsion occurred in 6/1449 and 20/3510 cases,
respectively. In real-world practice, this complication has clinical rele-
vance, demonstrated by two published series of SVC events in the
context of the use of compliant endovascular occlusion balloon: the
initial series reported 35 surgically confirmed cases of laser-related
SVC disruption in the USA during a 6-month period and the follow-
up series reported 116 SVC events in a 25-month period.15,16 Even
the lower of these estimates implies an average of more than 4 SVC
events per month.
The reported safety results of the PROMET study are in line with
the just recently published data of Diaz et al.,4 who compared the ob-
served mortality between laser and rotational extraction sheaths
based on the Manufacturer and User Facility Device Experience data-
base. At different market share estimates and with adjustment for po-
tential underreporting in cases with rotational sheaths the relative
....................................................................................................................................................................................................................
Table 2 Subgroup analysis of cases with the use of the Evolution rotational sheath vs. cases without Evolution
Evolution-group
(992 patients/1552 leads)
Non-Evolution group
(1213 patients/2297 leads)
P-value
Median implant duration 106 months (IQR 66–145) 58 months (IQR 28–90) <0.001
Complete procedural success (per lead) 95.2% 97.3% 0.003
Major complications 1.6% 0.5% <0.01
Procedure-related mortality 0.4% 0% <0.05
IQR, interquartile range.
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risk for mortality was significantly higher in laser sheath extractions
than in procedures with the use of a rotational extraction sheath.
Efficacy
The clinical success rate and complete procedural success rates for
leads targeted for removal in the PROMET series compare favour-
ably with other large patient cohorts in TLE procedures such as the
Lexicon study3 and the ELECTRa registry.17 The efficacy of the
Evolution rotational TLE device was proven by the achievement of
complete procedural success in more than 95% of leads with median
implant durations of 106 months, substantially longer than in previous
large TLE studies.3,17
Limitations
The major limitation of this study is its retrospective study design.
The acquired data represents real-world data in a number of centres
in different nations over a period of just over a decade. Due to the
retrospective design and the individual data recording in the different
participating centres, data recording may not have been complete in
all cases. Despite this fact, the authors believe that this data is of rele-
vant clinical importance for the lead extraction community and sup-
ports the hypothesis of a satisfactory safety profile and high efficacy
of rotational extraction sheaths, as seen in previous smaller
series.6,8,10,11,18
Conclusions
This large series of cases show that an extraction service based on ro-
tational dissecting tools can deliver a procedural mortality rate of
<0.2%, and that a service based on these products can deliver com-
plete lead extraction in over 96% of leads targeted. In this series, rota-
tional TLE tools showed a low incidence of major complications,
especially of SVC injuries. The efficacy of rotational TLE tools was
proven by the achievement of high success rates in leads with long
implant durations.
Funding
This study was supported by a research grant of Cook Medical (USA).
Conflict of interest: C.T.S. has received consulting fees and travel
expenses from Medtronic; consulting fees and research support from
Biotronik; research support from Abbott; workshop fees, consulting
fees, educational grants, and research support from Cook Medical; con-
sulting fees from Spectranetics/Philipps; consulting fees from
Angiodynamics. E.G. has received workshop fees and consulting fees
from Cook Medical. O.A.R. has received workshop fees from Cook
Medical. P.M. has received consulting fees from Boston Scientific,
Abbott and Cook Medical. A.B. has received consulting fees from
Abbott, Bayer Health Care, Biotronik, BMS/Pfizer, Boston Scientific,
Daiichy Sankio, and Medtronic. Educational grants from Biosense
Webster, Biotronik, and Actelion. Presenter fees from Abbott, Bayer
Health Care, Biotronik, BMS/Pfizer, Boston Scientific, Daiichy Sankio,
Medtronic, and Spectranetics/Philipps. J.S. has received consultant and/
or speaker fees from Abbott, Amgen, Astra-Zeneca, Atricure, Bayer,
Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific,
Bristol-Myers Squibb, Daiichi Sankyo, Medscape, Medtronic, Merck/
MSD, Novartis, Pfizer, Sanofi-Aventis, WebMD, and Zoll. He reports
ownership of CorXL. J.S. has received grant support through his institu-
tion from Abbott, Bayer Healthcare, Biosense Webster, Biotronik,
Boston Scientific, Daiichi Sankyo, and Medtronic. M.G. has received re-
search funding from Medtronic and Attune medical and has acted as a
consultant and paid speaker for Medtronic, Biosense Webster and
Cook Medical. P.P.D. has received consultant and/or speaker fees from
Abbott, Biotronik, Boston Scientific, Medtronic, EBR, MicroPort, and
Cook Mediccal. All other authors declare no conflict of interest.
References
1. Diemberger I, Mazzotti A, Giulia MB, Cristian M, Matteo M, Letizia ZM et al.
From lead management to implanted patient management: systematic review and
meta-analysis of the last 15 years of experience in lead extraction. Expert Rev
Med Devices 2013;10:551–73.
2. Wilkoff BL, Byrd CL, Love CJ, Hayes DL, Sellers TD, Schaerf R et al. Pacemaker
lead extraction with the laser sheath: results of the pacing lead extraction with
the excimer sheath (PLEXES) trial1. J Am Coll Cardiol 1999;33:1671–6.
3. Wazni O, Epstein LM, Carrillo RG, Love C, Adler SW, Riggio DW et al. Lead ex-
traction in the contemporary setting: the LExICon study. J Am Coll Cardiol 2010;
55:579–86.
....................................................................................................................................................................................................................
Table 4 Comparison of the results of the PROMET study with other published large volume studies
Patients/leads Indications Leads Implant duration
(months)
Success
rates
Major
complications
In-hospital
mortality
PROMET study 2205/3849 46.0% infection 74.8% pacemaker leads Mean 84.7 ± 61.8 96.5% CPS 1% 1.7% (30-day
mortality)
54.0% non-infectious 24.6% ICD leads Median 74.0 97.0%
0.6% unknown IQR (41.0–112.0) CS
LEXICON study 1449/2405 56.9% 70.0% pacemaker leads Median 82.1 96.5% CPS 1.4% 1.86%
Infection 29.2% ICD leads IQR (0.4–356.8) 97.7%
43.1% 0.7% unknown CS
Non-infectious
ELECTRa study 3510/4917 52.8% infection 75.7% pacemaker leads Mean 76.8 ± 64.8 95.7% CPS 1.7% 1.4%
47.3% non-infectious 24.3% ICD leads Median 60.0 96.7%
IQR (24.0–108.0) CS
CPS, complete procedural success; CS, clinical success; ICD, implantable cardioverter-defibrillator; IQR, interquartile range.
Results of the PROMET study 1109
4. Diaz CL, Guo X, Whitman IR, Marcus GM, Pellegrini CN, Beygui RE et al.
Reported mortality with rotating sheaths vs. laser sheaths for transvenous lead
extraction. Europace 2019;341:1882.
5. Hussein AA, Wilkoff BL, Martin DO, Karim S, Kanj M, Callahan T et al. Initial ex-
perience with the Evolution mechanical dilator sheath for lead extraction: safety
and efficacy. Heart Rhythm 2010;7:870–3.
6. Domenichini G, Gonna H, Sharma R, Conti S, Fiorista L, Jones S et al. Non-laser
percutaneous extraction of pacemaker and defibrillation leads: a decade of prog-
ress. Europace 2017;19:1521–6.
7. Yoshitake T, Goya M, Sasaki T, Shiohira S, Sekigawa M, Shirai Y et al. Safety and
efficacy of transvenous lead extraction with a high-frequency excimer laser—a
single center experience. Circ J 2018;82:2992–7.
8. Starck CT, Steffel J, Caliskan E, Holubec T, Schoenrath F, Maisano F et al. Clinical
performance of a new bidirectional rotational mechanical lead extraction sheath.
Europace 2016;18:253–6.
9. Starck CT, Stepuk A, Holubec T, Steffel J, Stark JW, Falk V. Compression coil
provides increased lead control in extraction procedures. Europace 2015;17:
499–503.
10. Sharma S, Ekeruo IA, Nand NP, Sundara Raman A, Zhang X, Reddy SK et al.
Safety and efficacy of transvenous lead extraction utilizing the evolution mechani-
cal lead extraction system: a single-center experience. JACC Clin Electrophysiol
2018;4:212–20.
11. Mazzone P, Migliore F, Bertaglia E, Facchin D, Daleffe E, Calzolari V et al. Safety
and efficacy of the new bidirectional rotational Evolution(R) mechanical lead ex-
traction sheath: results from a multicentre Italian registry. Europace 2018;20:
829–34.
12. Kusumoto FM, Schoenfeld MH, Wilkoff BL, Berul CI, Birgersdotter-Green UM,
Carrillo R et al. 2017 HRS expert consensus statement on cardiovascular im-
plantable electronic device lead management and extraction. Heart Rhythm 2017;
14:e503–51.
13. Wilkoff BL, Love CJ, Byrd CL, Bongiorni MG, Carrillo RG, Crossley GH et al.
Transvenous lead extraction: heart rhythm society expert consensus on facilities,
training, indications, and patient management. Heart Rhythm 2009;6:1085–104.
14. Bongiorni MG, Burri H, Deharo JC, Starck C, Kennergren C, Saghy L et al.; ESC
Scientific Document Group. 2018 EHRA expert consensus statement on lead
extraction: recommendations on definitions, endpoints, research trial design, and
data collection requirements for clinical scientific studies and registries: endorsed
by APHRS/HRS/LAHRS. Europace 2018;20:1217.
15. Azarrafiy R, Tsang DC, Boyle TA, Wilkoff BL, Carrillo RG. Compliant endovascu-
lar balloon reduces the lethality of superior vena cava tears during transvenous
lead extractions. Heart Rhythm 2017;14:1400–4.
16. Azarrafiy R, Tsang DC, Wilkoff BL, Carrillo RG. Endovascular occlusion balloon
for treatment of superior vena cava tears during transvenous lead extraction.
Circ Arrhythm Electrophysiol 2019;12:e007266.
17. Bongiorni MG, Kennergren C, Butter C, Deharo J-C, Kutarski A, Rinaldi CA
et al.; ELECTRa Investigators. The European Lead Extraction ConTRolled
(ELECTRa) study: a European Heart Rhythm Association (EHRA) registry of
transvenous lead extraction outcomes. Eur Heart J 2017;38:2995–3005.
18. Delnoy PPHM, Witte OA, Adiyaman A, Ghani A, Smit JJJ, Ramdat Misier AR
et al. Lead extractions: the Zwolle experience with the Evolution mechanical
sheath. Europace 2016;18:762–6.
1110 C.T. Starck et al.
